ENVYNZYBA Trademark

Trademark Overview

On Wednesday, June 8, 2022, a trademark application was filed for ENVYNZYBA with the United States Patent and Trademark Office. The USPTO has given the ENVYNZYBA trademark a serial number of 97449119. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, October 11, 2023. This trademark is owned by Genentech, Inc.. The ENVYNZYBA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical oncology preparations
envynzyba

General Information

Serial Number97449119
Word MarkENVYNZYBA
Filing DateWednesday, June 8, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, October 11, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 28, 2023

Trademark Statements

Goods and Servicespharmaceutical oncology preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, June 18, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenentech, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameGenentech, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Friday, October 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 11, 2023SOU EXTENSION 1 GRANTED
Wednesday, October 11, 2023SOU EXTENSION 1 FILED
Wednesday, October 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, April 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, April 19, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 19, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, April 19, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 19, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 28, 2023PUBLISHED FOR OPPOSITION
Wednesday, February 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 26, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 23, 2023ASSIGNED TO EXAMINER
Thursday, August 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 25, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, August 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, June 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 11, 2022NEW APPLICATION ENTERED

Related Keywords

envynzyba preparations oncology pharmaceutical